MedPath

Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB

Completed
Conditions
Inflammatory Response
Interventions
Registration Number
NCT02672345
Lead Sponsor
Instituto Dante Pazzanese de Cardiologia
Brief Summary

Cardiac surgery has evolved considerably after the advent of cardiopulmonary bypass (CPB), a feature that allowed more precision and tranquility to the heart surgeon. But their influence on exacerbation of inflammatory response can unbalance the whole homeostasis so happens surgical trauma. The attenuation of the systemic inflammatory response in major surgeries like cardiac surgery for aortic aneurysm appears to represent an important advance in reducing morbidity and mortality of these patients. Some studies suggest that inhaled anesthetics such as sevoflurane appear to play an important role in this control, but the mechanism by which this happens is still unclear. This study has the primary purpose of analyzing from a clinical study sevoflurane inhalation anesthetic can change the inflammatory response induced by CPB, significantly reducing the release of inflammatory markers, especially elastase PMN.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Age over 18 years
  • Cardiac Surgery elective of coronary artery bypass graft with cardiopulmonary bypass (CPB)
  • The informed consent signature savvy
Exclusion Criteria
  • Use of steroids or anti-inflammatory drugs routine
  • Presence of asthma, COPD, autoimmune diseases
  • Participation in other clinical studies
  • Presence of decompensated heart failures, liver or kidney
  • Combined elective surgery (ex .: aneurysm correction + CABG)
  • Acute myocardial infarction in the last 30 days
  • Unstable angina
  • And obesity (BMI> 50kg / m2)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sevoflurane GroupSevofluraneGroup of patients receiving sevorane during extracorporeal circulation period.
Primary Outcome Measures
NameTimeMethod
Reduction of systemic inflammatory responseThrough study completion, an average of 1 year

Cytokines are assayed in both groups at 4 different times in order to check the impact of sevoflurane on the inflammatory response. The first one is the baseline of measurement with which the others are compared and all will be compared within and between groups.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Thiago Augusto Azevedo Maranhão Cardoso

🇧🇷

São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath